Summary

Global Human Chorionic Gonadotropin (hCG) Market is valued at approximately USD 0.92 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.6 % over the forecast period 2022-2029. During pregnancy, the placenta secretes a hormone called human chorionic gonadotropin (hCG). It signals the body to cease menstruating and thickens the uterine lining to support a developing embryo. After fertilisation, HCG levels increase and stay elevated for another 10 weeks or more of pregnancy. While treating infertility in women, hCG is used to maintain the luteal phase, promote final follicular maturation, and cause ovulation. It is used to increase testosterone production in males by the Leydig cells in conditions such as hormone insufficiency and male hypogonadism. The increasing incidence of male hypogonadism among the geriatric population and the growing popularity of hCG among healthcare professionals are key factors driving the market growth.

Over the years the prevalence of hypogonadism among male is contributing towards the growth of the Global Human Chorionic Gonadotropin (hCG) Market. For instance – as per Boston University Medical Campus (BUMC) estimates - Hypogonadism affects an estimated 4 to 5 million men in the United States. Also, growing healthcare infrastructure in developing economies as well as the rising availability of recombinant hCGs in different dose strengths would create lucrative growth opportunities for the market over the projected period. However, concern over cautions and warnings issued by the FDA over the probable side effects of hCG therapy hinders the market growth throughout the forecast period of 2022-2029. For instance, in July 2020, The Food and Drug Administration (FDA) announced an advisory for consumers to avoid HCG weight-loss products.

The key regions considered for the Global Human Chorionic Gonadotropin (hCG) Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of leading market players as well as the rise in the incidence of infertility-related problems both in males and females. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing expansion of healthcare facilities in the region.

Major market player included in this report are:
Bristol Myers Squibb Company
Ferring Pharmaceuticals Inc
Merck & Co., Inc
Fresenius Kabi AG
Cigna
Sun Pharmaceutical Industries Ltd
Lee BioSolutions Inc
Sanzyme Biologics Private Ltd.
Scripps Laboratories Inc.
LUPIN Limited

Recent Developments in the Market:
 In july 2020, The FDA eliminated hCG, a weight-loss ingredient, from marketable products. The FDA continued by stating that all over-the-counter medications and diets that advertise the use of hCG as a weight-loss ingredient are false and illegal and that there is also no evidence to support the claims made. FDA continued by stating that the restriction of 500 calories per day while using the supplement has been introduced by the product sellers, which could be lethal.




Global Human Chorionic Gonadotropin (hCG) Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Technology, Therapeutic Area, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology
Natural Source Extraction
Recombinant Technology
By Therapeutic Area
Female Infertility Treatment
Male Hypogonadism
Oligospermic Treatment
By End User
Fertility Clinics
Research Institutes


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Human Chorionic Gonadotropin (hCG) Market, by Region, 2019-2029 (USD Billion)
1.2.2. Human Chorionic Gonadotropin (hCG) Market, by Technology, 2019-2029 (USD Billion)
1.2.3. Human Chorionic Gonadotropin (hCG) Market, by Therapeutic Area, 2019-2029 (USD Billion)
1.2.4. Human Chorionic Gonadotropin (hCG) Market, by End User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Human Chorionic Gonadotropin (hCG) Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Human Chorionic Gonadotropin (hCG) Market Dynamics
3.1. Human Chorionic Gonadotropin (hCG) Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing incidence of male hypogonadism among the geriatric population
3.1.1.2. Growing popularity of hCG among healthcare professionals
3.1.2. Market Challenges
3.1.2.1. Concern over cautions and warnings issued by the FDA pertaining to the side effects of hCG therapy.
3.1.3. Market Opportunities
3.1.3.1. Growing healthcare infrastructure in developing economies
3.1.3.2. Rising availability of recombinant hCGs in different dose strengths
Chapter 4. Global Human Chorionic Gonadotropin (hCG) Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Human Chorionic Gonadotropin (hCG) Market, by Technology
6.1. Market Snapshot
6.2. Global Human Chorionic Gonadotropin (hCG) Market by Technology, Performance - Potential Analysis
6.3. Global Human Chorionic Gonadotropin (hCG) Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
6.4. Human Chorionic Gonadotropin (hCG) Market, Sub Segment Analysis
6.4.1. Natural Source Extraction
6.4.2. Recombinant Technology
Chapter 7. Global Human Chorionic Gonadotropin (hCG) Market, by Therapeutic Area
7.1. Market Snapshot
7.2. Global Human Chorionic Gonadotropin (hCG) Market by Therapeutic Area, Performance - Potential Analysis
7.3. Global Human Chorionic Gonadotropin (hCG) Market Estimates & Forecasts by Therapeutic Area 2019-2029 (USD Billion)
7.4. Human Chorionic Gonadotropin (hCG) Market, Sub Segment Analysis
7.4.1. Female Infertility Treatment
7.4.2. Oligospermic treatment
7.4.3. Male hypogonadism
Chapter 8. Global Human Chorionic Gonadotropin (hCG) Market, by End User
8.1. Market Snapshot
8.2. Global Human Chorionic Gonadotropin (hCG) Market by End User, Performance - Potential Analysis
8.3. Global Human Chorionic Gonadotropin (hCG) Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
8.4. Human Chorionic Gonadotropin (hCG) Market, Sub Segment Analysis
8.4.1. Fertility Clinics
8.4.2. Research Institutions
Chapter 9. Global Human Chorionic Gonadotropin (hCG) Market, Regional Analysis
9.1. Human Chorionic Gonadotropin (hCG) Market, Regional Market Snapshot
9.2. North America Human Chorionic Gonadotropin (hCG) Market
9.2.1. U.S. Human Chorionic Gonadotropin (hCG) Market
9.2.1.1. Technology breakdown estimates & forecasts, 2019-2029
9.2.1.2. Therapeutic Area breakdown estimates & forecasts, 2019-2029
9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Human Chorionic Gonadotropin (hCG) Market
9.3. Europe Human Chorionic Gonadotropin (hCG) Market Snapshot
9.3.1. U.K. Human Chorionic Gonadotropin (hCG) Market
9.3.2. Germany Human Chorionic Gonadotropin (hCG) Market
9.3.3. France Human Chorionic Gonadotropin (hCG) Market
9.3.4. Spain Human Chorionic Gonadotropin (hCG) Market
9.3.5. Italy Human Chorionic Gonadotropin (hCG) Market
9.3.6. Rest of Europe Human Chorionic Gonadotropin (hCG) Market
9.4. Asia-Pacific Human Chorionic Gonadotropin (hCG) Market Snapshot
9.4.1. China Human Chorionic Gonadotropin (hCG) Market
9.4.2. India Human Chorionic Gonadotropin (hCG) Market
9.4.3. Japan Human Chorionic Gonadotropin (hCG) Market
9.4.4. Australia Human Chorionic Gonadotropin (hCG) Market
9.4.5. South Korea Human Chorionic Gonadotropin (hCG) Market
9.4.6. Rest of Asia Pacific Human Chorionic Gonadotropin (hCG) Market
9.5. Latin America Human Chorionic Gonadotropin (hCG) Market Snapshot
9.5.1. Brazil Human Chorionic Gonadotropin (hCG) Market
9.5.2. Mexico Human Chorionic Gonadotropin (hCG) Market
9.5.3. Rest of Latin America Human Chorionic Gonadotropin (hCG) Market
9.6. Rest of The World Human Chorionic Gonadotropin (hCG) Market

Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Bristol Mayer Squibb Limited
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Ferring Pharmaceuticals Inc
10.2.3. Merck & Co., Inc
10.2.4. Fresenius Kabi AG
10.2.5. Cigna
10.2.6. Sun Pharmaceutical Industries Ltd
10.2.7. Lee BioSolutions Inc
10.2.8. Sanzyme Biologics Private Ltd.
10.2.9. Scripps Laboratories Inc.
10.2.10. LUPIN Limited
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption